The VE market's heat recovery drives profit growth, Nachi Bearings Shanghai Rongsheng. The company's synthetic VE series revenue increased by 15% year-on-year, accounting for 52.7% of the company's business income and 67.8% of the gross margin, making it the most important source of the company's profits; in the fourth quarter of 09, single-season profits reached a historical high; in the fourth quarter of 09, the company achieved earnings per share of 1.07 yuan, with net profits belonging to the parent company reaching a historical high; new drug research and development and process improvements have made significant progress. The company's patented drug Changxin Sanding has entered phase one clinical trials; the quality of isoprenol has greatly improved, as well as the fermentation levels of vancomycin and *** ranidin, which will significantly reduce the cost of beta-carotene; Dragon Boat Festival diary.
Xianju Pharmaceutical's listing enhances the company's value. Zhejiang Pharma owns 6.75% of Xianju Pharmaceutical's equity, and its listing has increased the value of this part of the company's equity by 1.41 billion yuan, possibly contributing substantial investment returns in the future.
Maintain a recommendation for the investment rating, automotive hydraulic pump. Vitamin E is currently in the process of recovering prosperity in the second quarter, and it is expected that the company's net profit will still increase in 2010. Zhejiang Medicine also has varieties such as Changxin Sanding and Puzhuang Acid Prutinin in patented drugs, and there is also potential for breakthroughs in formulation exports. The company's valuation is the lowest in the pharmaceutical sector, maintaining a recommended investment rating.
Related thematic articles: Xin Xin's total burn area reaches 60%, waiting online. The unit energy consumption of major products in eight high-energy-consuming industries is on average 40% higher than international advanced levels.